Voriconazole treatment for less-common, emerging, or refractory fungal infections.


Journal Article

Treatments for invasive fungal infections remain unsatisfactory. We evaluated the efficacy, tolerability, and safety of voriconazole as salvage treatment for 273 patients with refractory and intolerant-to-treatment fungal infections and as primary treatment for 28 patients with infections for which there is no approved therapy. Voriconazole was associated with satisfactory global responses in 50% of the overall cohort; specifically, successful outcomes were observed in 47% of patients whose infections failed to respond to previous antifungal therapy and in 68% of patients whose infections have no approved antifungal therapy. In this population at high risk for treatment failure, the efficacy rates for voriconazole were 43.7% for aspergillosis, 57.5% for candidiasis, 38.9% for cryptococcosis, 45.5% for fusariosis, and 30% for scedosporiosis. Voriconazole was well tolerated, and treatment-related discontinuations of therapy or dose reductions occurred for <10% of patients. Voriconazole is an effective and well-tolerated treatment for refractory or less-common invasive fungal infections.

Full Text

Duke Authors

Cited Authors

  • Perfect, JR; Marr, KA; Walsh, TJ; Greenberg, RN; DuPont, B; de la Torre-Cisneros, J; Just-Nübling, G; Schlamm, HT; Lutsar, I; Espinel-Ingroff, A; Johnson, E

Published Date

  • May 1, 2003

Published In

Volume / Issue

  • 36 / 9

Start / End Page

  • 1122 - 1131

PubMed ID

  • 12715306

Pubmed Central ID

  • 12715306

Electronic International Standard Serial Number (EISSN)

  • 1537-6591

Digital Object Identifier (DOI)

  • 10.1086/374557


  • eng

Conference Location

  • United States